• Á¤¿õ±â
    º´¿øÀå
    (ÀÇÇйڻç, ¹æ»ç¼±Á¾¾çÇаú Àü¹®ÀÇ)

  • Àü¹®ºÐ¾ß
  • ¹æ»ç¼±Á¾¾çÇÐ (µÎ°æºÎ¾Ï, ³úÁ¾¾ç, ¸²ÇÁÁ¾)
  •  
  • ÇзÂ
  • ¤ý1973.3 ~1979.2
  • Àü³²´ëÇб³ Àǰú´ëÇÐ ÀÇÇлç
  • ¤ý1979.3 ~1983.2
  • Àü³²´ëÇб³º´¿ø ÀÎÅÏ ¹× ¹æ»ç¼±°ú Àü°øÀÇ °úÁ¤ ¼ö·á
  • ¤ý1980.3 ~1982.2
  • Àü³²´ëÇб³ ´ëÇпø ÀÇÇÐ ¼®»ç
  • ¤ý1991.8
  • Àü³²´ëÇб³ ´ëÇпø ÀÇÇÐ ¹Ú»ç ÇÐÀ§ Ãëµæ
  •  
  •  
  • °æ·Â
  •  
  • ¤ý1983.4 ~ 1986.4
  • °øÁߺ¸°ÇÀÇ»ç
  • ¤ý1986.5 ~ 1988.2
  • ¾Æ»êº¹ÁöÀç´Ü º¸¼ºº´¿ø ¹æ»ç¼±°úÀå
  • ¤ý1988.3 ~ 1989.8
  • ¼­¿ï´ëÇб³º´¿ø ¹æ»ç¼±Á¾¾çÇаú ÀüÀÓÀÇ»ç
  • ¤ý1989.9 ~ ÇöÀç
  • Àü³²´ëÇб³ Àǰú´ëÇÐ ¹æ»ç¼±Á¾¾çÇб³½Ç, ±³¼ö
  • ¤ý1999.3 ~ 2005.3
  • Àü³²´ëÇб³º´¿ø ¹æ»ç¼±Á¾¾çÇаúÀå
  • ¤ý2002.6 ~ 2008.6
  • Àü³²´ëÇб³º´¿ø Çи¶À»ºÀ»çȸ ºÎȸÀå
  • ¤ý2003.3 ~ 2013.2
  • Àü³²ÀÇ´ë ¹æ»ç¼±Á¾¾çÇб³½Ç ÁÖÀÓ±³¼ö
  • ¤ý2004.4 ~ 2006.4
  • È­¼øÀü³²´ëÇб³º´¿ø ¹æ»ç¼±Á¾¾çÇаúÀå
  • ¤ý2006.10 ~ 2008.10
  • ´ëÇѹæ»ç¼±Á¾¾çÇÐȸ ºÎȸÀå
  • ¤ý2007.3 ~ 2008.3
  • Àü³²´ëÇб³º´¿ø È«º¸½ÇÀå
  • ¤ý2013.12 ~ 2015.3
  • È­¼øÀü³²´ëÇб³º´¿ø Áø·áóÀå
  • ¤ý2020.1 ~ ÇöÀç
  • È­¼ø±º¸³¿ä¾çº´¿ø º´¿øÀå
  •  
  •  
  • ÇÐȸ ¹× »çȸȰµ¿
  •  
  • ´ëÇÑ ¹æ»ç¼±Á¾¾çÇÐȸ Á¤È¸¿ø
  • ´ëÇÑ ¾ÏÇÐȸ Á¤È¸¿ø
  • ´ëÇÑ ¿µ»óÀÇÇÐȸ Á¤È¸¿ø
  • ´ëÇÑ ÀÇÇй°¸®ÇÐȸ ȸ¿ø
  • ´ëÇÑ ¹æ»ç¼± ¹æ¾îÇÐȸ Á¤È¸¿ø
  • À¯·´ ¹æ»ç¼± Á¾¾çÇÐȸ ±¹Á¦È¸¿ø
  • ¹Ì±¹ ¹æ»ç¼±Á¾¾çÇÐȸ ±¹Á¦È¸¿ø
  •  
  •  
  • ÇØ¿Ü¿¬¼ö
  •  
  • ¤ý1990.10
  • ¹Ì±¹, ¿ÀÇÏÀÌ¿À, Cleveland, Metrohealth Hospital ¿¬¼ö
  • ¤ý1995.1 ¡­ 1996.1
  • ¹Ì±¹, ÅØ»ç½º´ë. M.D. Anderson Cancer Center ¿¬¼ö
  • ¤ý2004.4
  • ¹Ì±¹, ´º¿å, ½Ã¶óÅ¥½º, Upstate Medical University Hospital ¿¬¼ö
  •  
  •  
  • ¸éÇã ¹× ÀÚ°ÝÁõ
  •  
  • ¤ý1979.2
  • ÀÇ»ç¸éÇã
  • ¤ý1983.4
  • Áø´Ü ¹× Ä¡·á¹æ»ç¼±°úÀü¹®ÀÇ Ãëµæ
  • ¤ý1986.1
  • ¹æ»ç¼ºµ¿À§¿ø¼ÒÃë±ÞÀÚ Æ¯¼ö¸éÇãÃëµæ
  • ¤ý1991
  • ÀÇÇйڻç ÇÐÀ§ Ãëµæ
  •  
  •  
  • ¼ö»ó³»¿ª
  •  
  • ¤ý2003.9.26
  • ¹ýÀÎÈ­ 10³â ±Ù¼Ó, Àü³²´ëº´¿øÀå ǥâ(Á¦827È£)
  • ¤ý2003.9.26
  • Àü³²´ëº´¿øÀå ǥâ(Á¦1553È£)
  • ¤ý2006.9.26
  • Àü³²´ëº´¿øÀå ǥâ(Á¦2075È£)
  • ¤ý2010.6.28
  • 20³â ±Ù¼Ó Àü³²´ë ÃÑÀå ǥâ(Á¦10295È£)
  •  
  •  
  • ÃÖ±Ù ¿¬±¸ ¾÷Àû
  •  
  • 1. Survival outcomes of breast cancer patients with brain metastases: A multicenter retrospective study in Korea (KROG 16-12) (BREAST 2019; 49(1):41-47)
  • 2. Prognostic significance of lymphovascular invasion in patients with prostate cancer treated with postoperative radiotherapy (Radiation oncology journal. 2019. 37(3); 215-223)
  • 3. Validation of a novel molecular RPA classification in glioblastoma (GBM-molRPA) treated with chemoradiation: A multi-institutional collaborative study. (Radiotherapy Oncology. 2018. 129(2);347-351)
  • 4. p16 as a prognostic factor for the response to induction chemotherapy in advanced hypopharyngeal squamous cell carcinoma. (Oncolgy Letters. 2018. 15(5);6571-6577)
  • 5. The role of interim FDG PET-CT after induction chemotherapy as a predictor of concurrent chemoradiotherapy efficacy and prognosis for head and neck cancer. (European Journal of Nuclear Medicine and Molecular Imaging. 2018. 45(2);170-178)
  • 6. Correlation of biologically effective dose and the tumor control in Stage I (<5 cm) non-small cell lung cancer with stereotactic ablative radiotherapy: a single institutional cohort study. (Japanese Journal Of Clinical Oncology. 2018. 48(2); 144-152)
  • 7. Effect of irradiation-induced intercellular adhesion molecule-1 expression on natural killer cell-mediated cytotoxicity toward human cancer cells. (Cytotherapy. 2018. 20(5);715-727)
  •  
  •